Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The European Federation for Pharmaceutical Sciences (EUFEPS) today awarded the Giorgio Segré Prize to Professor Joel Tarning for his scientific research work on the pharmacokinetic and pharmacodynamic properties of antimalarial drugs in vulnerable populations, such as pregnant women and young children.

Joel Tarning

Based in Bangkok, Thailand, Professor Tarning leads a diverse team of 30 scientists studying clinical pharmacology at the Mahidol Oxford Tropical Medicine Research Unit (MORU), a research collaboration between Mahidol University in Thailand and Oxford University and the Wellcome Trust in the UK. The team has responsibilities within pharmacometric data analysis, bioanalytical method development, drug quantification of clinical samples and omics-based research. Professor Tarning is also the Head of the Pharmacometric Modelling Group at the Worldwide Antimalarial Resistance Network (WWARN).

The main focus of Professor Tarning’s research is antimalarial dose-optimisation in vulnerable populations at risk of treatment failure and resistance development, such as children and pregnant women. He has built a group that develops and uses integrated models for disease transmission, parasite dynamics, drug action, resistance development, pharmacokinetics and patient population characteristics.

“Dr Tarning has demonstrated that he can integrate trial design, data collection and data analysis to respond to a trial aim and also contribute to defining this aim, knowledgeably and efficiently” noted the EUFEPS in its award statement. “His work on population pharmacokinetic-pharmacodynamic modelling of oral dihydroartemisinin-piperaquine in children with uncomplicated malaria, and intramuscular artesunate in children with severe malaria, started the debate on new dose recommendations in young children which has informed revised WHO guidelines for the treatment of malaria."

Based in Järfälla, Sweden, EUFEPS serves and advances excellence in the pharmaceutical sciences and innovative drug research in Europe. Founded in 1991, EUFEPS publishes European Journal of Pharmaceutical Sciences, its monthly official scientific journal. The Giorgio Segré Prize is awarded by EUFEPS on a biennial basis to young researchers who have made significant contributions to the pharmacologic discipline of pharmacokinetics-pharmacodynamics, which studies the effects in patients of administered drug doses over time.

Prof Philippe Guérin, Director of WWARN, said: “Professor Tarning’s work has made a significant contribution to our understanding of the optimal dosing for key antimalarial medicines used to treat children with malaria. The award is a fitting recognition of his work and we are delighted that the EUFPS have acknowledged its significance.”

For press enquiries, please contact:

Per Öhrngren, European Federation for Pharmaceutical Sciences (EUFEPS)

Anne Whitehouse, Worldwide Antimalarial Resistance Network (WWARN), Centre for Tropical Medicine & Global Health, University of Oxford; tel. +44(0)1865 857 412 or + 44 (0) 7812 165 934

For Asia-based MORU enquiries: John Bleho, Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand; tel. +66 81 750 0539

For the Wellcome Trust, please contact Clare Ryan; tel. +44 207 611 7262

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.